Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
63.80 USD | -0.22% |
|
-4.29% | +42.13% |
07-16 | Bernstein Adjusts Price Target on CVS Health to $72 From $78, Maintains Market Perform Rating | MT |
07-15 | CVS Beats Out UnitedHealth for Calpers Pharmacy Benefits Deal -- Update | DJ |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.77 | 3.71 | 4.18 | 3.68 | 1.99 | |||||
Return on Total Capital | 5.55 | 5.63 | 6.57 | 5.89 | 3.19 | |||||
Return On Equity % | 10.76 | 10.89 | 5.68 | 11.28 | 6.02 | |||||
Return on Common Equity | 10.79 | 10.95 | 5.68 | 11.28 | 6.07 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 18.01 | 17.48 | 16.62 | 14.94 | 13.29 | |||||
SG&A Margin | 12.91 | 12.74 | 11.83 | 10.99 | 11.12 | |||||
EBITDA Margin % | 6.76 | 6.29 | 6.11 | 5.17 | 3.4 | |||||
EBITA Margin % | 5.97 | 5.51 | 5.36 | 4.48 | 2.71 | |||||
EBIT Margin % | 5.1 | 4.74 | 4.79 | 3.95 | 2.16 | |||||
Income From Continuing Operations Margin % | 2.69 | 2.71 | 1.29 | 2.35 | 1.24 | |||||
Net Income Margin % | 2.68 | 2.72 | 1.29 | 2.34 | 1.24 | |||||
Net Avail. For Common Margin % | 2.68 | 2.72 | 1.29 | 2.34 | 1.24 | |||||
Normalized Net Income Margin | 2.69 | 2.68 | 2.71 | 2.19 | 1.22 | |||||
Levered Free Cash Flow Margin | 4.8 | 5.01 | 3.74 | 3.11 | 1.86 | |||||
Unlevered Free Cash Flow Margin | 5.48 | 5.55 | 4.18 | 3.57 | 2.36 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.18 | 1.25 | 1.39 | 1.49 | 1.47 | |||||
Fixed Assets Turnover | 8.09 | 8.9 | 10.25 | 11.66 | 12.49 | |||||
Receivables Turnover (Average Receivables) | 14.57 | 14.34 | 14.34 | 16.63 | 24.52 | |||||
Inventory Turnover (Average Inventory) | 12.2 | 13.24 | 14.55 | 16.35 | 17.79 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.91 | 0.88 | 0.94 | 0.86 | 0.81 | |||||
Quick Ratio | 0.53 | 0.55 | 0.62 | 0.59 | 0.56 | |||||
Operating Cash Flow to Current Liabilities | 0.26 | 0.27 | 0.23 | 0.17 | 0.11 | |||||
Days Sales Outstanding (Average Receivables) | 25.12 | 25.46 | 25.46 | 21.95 | 14.93 | |||||
Days Outstanding Inventory (Average Inventory) | 30 | 27.56 | 25.08 | 22.33 | 20.57 | |||||
Average Days Payable Outstanding | 17.94 | 18.06 | 18.54 | 17.95 | 17.53 | |||||
Cash Conversion Cycle (Average Days) | 37.18 | 34.96 | 31.99 | 26.33 | 17.97 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 122.01 | 100.82 | 99.18 | 103.59 | 109.49 | |||||
Total Debt / Total Capital | 54.96 | 50.2 | 49.79 | 50.88 | 52.27 | |||||
LT Debt/Equity | 111.85 | 93.06 | 94.34 | 97.44 | 99.6 | |||||
Long-Term Debt / Total Capital | 50.38 | 46.34 | 47.36 | 47.86 | 47.54 | |||||
Total Liabilities / Total Assets | 69.79 | 67.65 | 68.76 | 69.31 | 70.09 | |||||
EBIT / Interest Expense | 4.7 | 5.5 | 6.74 | 5.29 | 2.71 | |||||
EBITDA / Interest Expense | 7.34 | 8.59 | 9.98 | 8.11 | 5.29 | |||||
(EBITDA - Capex) / Interest Expense | 6.5 | 7.58 | 8.79 | 6.97 | 4.35 | |||||
Total Debt / EBITDA | 3.99 | 3.54 | 3.1 | 3.68 | 5.3 | |||||
Net Debt / EBITDA | 3.48 | 2.95 | 2.41 | 3.15 | 4.6 | |||||
Total Debt / (EBITDA - Capex) | 4.5 | 4.01 | 3.52 | 4.28 | 6.45 | |||||
Net Debt / (EBITDA - Capex) | 3.92 | 3.34 | 2.74 | 3.67 | 5.59 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 4.75 | 8.59 | 10.56 | 10.88 | 3.93 | |||||
Gross Profit, 1 Yr. Growth % | 8.38 | 5.39 | 5.13 | -0.72 | -7.56 | |||||
EBITDA, 1 Yr. Growth % | 11.83 | 1.02 | 5.99 | -7.65 | -31.58 | |||||
EBITA, 1 Yr. Growth % | 12.28 | 0.2 | 5.68 | -8.84 | -37.14 | |||||
EBIT, 1 Yr. Growth % | 15.61 | 0.83 | 9.81 | -10.6 | -43.02 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 8.6 | 9.68 | -47.27 | 93.39 | -45.2 | |||||
Net Income, 1 Yr. Growth % | 8.22 | 10.18 | -47.55 | 93.55 | -44.7 | |||||
Normalized Net Income, 1 Yr. Growth % | 17.66 | 8.39 | 9.31 | -12.2 | -42.08 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 7.68 | 8.78 | -47.23 | 98.47 | -43.43 | |||||
Accounts Receivable, 1 Yr. Growth % | 13.39 | 7.66 | 13.24 | -42.73 | -6.47 | |||||
Inventory, 1 Yr. Growth % | 5.59 | -3.98 | 7.49 | -5.58 | 0.45 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.31 | -3.95 | -3.98 | -1.01 | -4.92 | |||||
Total Assets, 1 Yr. Growth % | 3.72 | 0.99 | -2.03 | 9.4 | 1.4 | |||||
Tangible Book Value, 1 Yr. Growth % | -15.71 | -19.93 | -3.58 | 39.9 | -2.29 | |||||
Common Equity, 1 Yr. Growth % | 8.65 | 8.19 | -5.41 | 6.98 | -1.18 | |||||
Cash From Operations, 1 Yr. Growth % | 23.48 | 15.13 | -11.43 | -17.01 | -32.17 | |||||
Capital Expenditures, 1 Yr. Growth % | -0.81 | 3.41 | 8.21 | 11.15 | -8.25 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 26.5 | 13.21 | -18.42 | -7.21 | -37.62 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 21.67 | 9.86 | -17.48 | -4.7 | -31.24 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 10 | 10 | 9.92 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 17.54 | 6.65 | 9.57 | 10.72 | 7.35 | |||||
Gross Profit, 2 Yr. CAGR % | 25 | 6.88 | 5.26 | 2.29 | -4.2 | |||||
EBITDA, 2 Yr. CAGR % | 19.07 | 6.29 | 4.22 | -0.55 | -20.51 | |||||
EBITA, 2 Yr. CAGR % | 20.31 | 6.07 | 3.74 | -1.26 | -24.3 | |||||
EBIT, 2 Yr. CAGR % | 16.59 | 7.97 | 6.22 | -0.3 | -28.63 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 247.59 | 9.14 | -23.95 | 2.34 | 2.95 | |||||
Net Income, 2 Yr. CAGR % | 247.65 | 9.19 | -23.98 | 2.12 | 3.45 | |||||
Normalized Net Income, 2 Yr. CAGR % | 19.31 | 12.93 | 9.99 | -1.35 | -28.69 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 209.28 | 8.22 | -24.23 | 3.67 | 5.96 | |||||
Accounts Receivable, 2 Yr. CAGR % | 10.28 | 10.49 | 10.41 | -13.84 | -26.81 | |||||
Inventory, 2 Yr. CAGR % | 6.04 | 0.69 | 1.59 | 0.74 | -2.61 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 71.38 | -1.36 | -3.96 | -2.5 | -2.98 | |||||
Total Assets, 2 Yr. CAGR % | 8.37 | 2.34 | -0.53 | 3.53 | 5.32 | |||||
Tangible Book Value, 2 Yr. CAGR % | -14.86 | -17.85 | -12.13 | 15.4 | 16.91 | |||||
Common Equity, 2 Yr. CAGR % | 9.17 | 8.42 | 1.16 | 0.92 | 2.82 | |||||
Cash From Operations, 2 Yr. CAGR % | 33.78 | 19.23 | 0.98 | -14.26 | -24.97 | |||||
Capital Expenditures, 2 Yr. CAGR % | 9.38 | 1.27 | 5.78 | 9.67 | 0.99 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 1.14 | 19.67 | -3.36 | -13.44 | -23.92 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 1.64 | 15.62 | -4.3 | -11.73 | -19.05 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 4.88 | 10 | 9.96 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 13.18 | 14.48 | 7.94 | 10 | 8.41 | |||||
Gross Profit, 3 Yr. CAGR % | 19.17 | 18.09 | 6.29 | 3.36 | -1.11 | |||||
EBITDA, 3 Yr. CAGR % | 13.91 | 12.72 | 6.7 | 0.61 | -12.21 | |||||
EBITA, 3 Yr. CAGR % | 14.77 | 13.19 | 6.51 | -0.05 | -15.06 | |||||
EBIT, 3 Yr. CAGR % | 11.83 | 11.08 | 9.27 | 0.99 | -17.26 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 2.79 | 136.64 | -14.36 | 5.13 | -16.89 | |||||
Net Income, 3 Yr. CAGR % | 2.73 | 137.03 | -14.48 | 5.14 | -16.76 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.7 | 15.56 | 12.49 | 2.82 | -17.39 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -5.35 | 118.31 | -14.82 | 5.76 | -15.28 | |||||
Accounts Receivable, 3 Yr. CAGR % | 14.45 | 9.4 | 11.4 | -7.19 | -11.45 | |||||
Inventory, 3 Yr. CAGR % | 6.54 | 2.59 | 2.91 | -0.86 | 0.65 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 47.96 | 41.3 | -2.24 | -2.99 | -3.32 | |||||
Total Assets, 3 Yr. CAGR % | 34.35 | 5.85 | 0.87 | 2.67 | 2.81 | |||||
Tangible Book Value, 3 Yr. CAGR % | 42.12 | -16.58 | -13.34 | 2.16 | 9.17 | |||||
Common Equity, 3 Yr. CAGR % | 22.56 | 8.84 | 3.6 | 3.29 | 0.21 | |||||
Cash From Operations, 3 Yr. CAGR % | 25.6 | 27.25 | 7.98 | -5.41 | -20.7 | |||||
Capital Expenditures, 3 Yr. CAGR % | 8.31 | 7.35 | 3.54 | 7.54 | 3.34 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 29.88 | 5.02 | 5.72 | -4.88 | -22.4 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 30.97 | 4.31 | 3.67 | -4.64 | -18.78 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | 3.23 | 6.56 | 9.97 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 11.81 | 10.38 | 11.72 | 12.96 | 7.7 | |||||
Gross Profit, 5 Yr. CAGR % | 12.71 | 11.99 | 13.4 | 11.53 | 2.04 | |||||
EBITDA, 5 Yr. CAGR % | 8.96 | 6.98 | 9.93 | 7.63 | -4.86 | |||||
EBITA, 5 Yr. CAGR % | 9.2 | 7.12 | 10.22 | 7.64 | -6.76 | |||||
EBIT, 5 Yr. CAGR % | 7.1 | 5.43 | 9.55 | 6.96 | -7.46 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 6.61 | 8.22 | -8.88 | 69.62 | -7.11 | |||||
Net Income, 5 Yr. CAGR % | 6.51 | 8.27 | -8.93 | 69.64 | -7 | |||||
Normalized Net Income, 5 Yr. CAGR % | 5.33 | 5.59 | 9.82 | 9.12 | -5.82 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 3.44 | 3.92 | -13.41 | 62.45 | -6.35 | |||||
Accounts Receivable, 5 Yr. CAGR % | 10.45 | 11.58 | 12.82 | -0.57 | -3.25 | |||||
Inventory, 5 Yr. CAGR % | 5.73 | 3.77 | 4.53 | 1.85 | 0.67 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 27.6 | 25.77 | 24.47 | 21.81 | -2.54 | |||||
Total Assets, 5 Yr. CAGR % | 20.07 | 19.79 | 19.13 | 4.92 | 2.62 | |||||
Tangible Book Value, 5 Yr. CAGR % | 22.81 | 17.24 | 17.25 | -5.02 | -2.57 | |||||
Common Equity, 5 Yr. CAGR % | 13.28 | 15.31 | 13.51 | 5.6 | 3.42 | |||||
Cash From Operations, 5 Yr. CAGR % | 13.19 | 12.49 | 15.1 | 8.66 | -6.65 | |||||
Capital Expenditures, 5 Yr. CAGR % | 0.58 | 2.53 | 7.29 | 8.27 | 2.51 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 14.39 | 13.32 | 15.4 | -2.52 | -7.45 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 15.72 | 13.75 | 15.52 | -2.18 | -6.22 | |||||
Dividend Per Share, 5 Yr. CAGR % | 7.39 | 3.3 | 1.92 | 3.89 | 5.87 |
- Stock Market
- Equities
- CVS Stock
- Financials CVS Health Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition